How Will the Organ Transplant Immunosuppressant Drugs Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the organ transplant immunosuppressant drugs market right now?
The market size for immunosuppressant drugs used in organ transplants has seen consistent growth over recent years. Its growth is projected to continue from $5.35 billion in 2024, increasing to $5.52 billion in 2025, revealing a compound annual growth rate (CAGR) of 3.2%. The expansion experienced in the earlier period has been influenced by a rise in the number of transplant procedures, enhancement in healthcare infrastructure, progress in research and development, an aging global populace, and heightened awareness.
How fast Is the organ transplant immunosuppressant drugs market expected to grow, and what’s its future value?
It is projected that the market size of organ transplant immunosuppressant drugs will experience consistent expansion in the approaching years. The market is set to reach “$6.61 billion by 2029, with a compound annual growth rate (CAGR) of 4.6%. The expected growth in this period is due to the emergence of new therapies, an increase in organ failure cases, advancements in personalized medicine, worldwide health campaigns, and global cooperation. The forthcoming period will be characterized by technological breakthroughs, advances in technology, strategies to reduce costs, market amalgamation and collaborations, and an incline in the number of organ transplants.
Get your organ transplant immunosuppressant drugs market report here!
What are the leading drivers of growth in the organ transplant immunosuppressant drugs market?
The organ transplant immunosuppressant drugs market is set to expand due to the growing need for organ transplantation. The practice of organ transplantation involves substituting a patient’s defective or failing organ with a healthy one from a donor, presenting a crucial lifeline for many. Immunosuppressant medications play a critical role in preventing the body from rejecting the new organ, which could otherwise result in organ rejection. Hence, the ready supply and efficacy of these drugs are instrumental in ensuring successful organ transplants. For instance, the Organ Procurement and Transplantation Network (OPTN), a public-private entity in the US, reported in 2023 that about 16,335 individuals collectively opted to donate one or more organs posthumously. This is the inaugural year with over 15,000 deceased donors, marking a 9.6% uplift from 2022. Thus, the rising demand for organ transplantation is likely to fuel the organ transplant immunosuppressant drugs market.
What are the key segments defining the organ transplant immunosuppressant drugs market?
The organ transplant immunosuppressant drugs market covered in this report is segmented –
1) By Drug Class: Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Others Drug Classes
2) By Transplant Type: Heart, Kidney, Liver, Lung, Pancreas, Other Transplant Types
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Calcineurin Inhibitors: Cyclosporine, Tacrolimus
2) By Antiproliferative Agents: Azathioprine, Mycophenolate Mofetil, Mycophenolic Acid
3) By MTOR Inhibitor: Sirolimus, Everolimus
4) By Steroids: Prednisone, Methylprednisolone
5) By Other Drug Classes: Costimulation Blockers, Sodium Channel Blockers, Antibody-Based Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10143&type=smp
Who are the key players steering the development of the organ transplant immunosuppressant drugs market?
Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited
What emerging trends are influencing the growth of the organ transplant immunosuppressant drugs market?
Product advancement is a prevalent trend in the organ transplant immunosuppressant drug industry. Leading firms this space are strategizing on unique solutions such as combination therapy for staying competitive. The blend of two or more immunosuppressant medications is gaining traction as it could offer enhanced immunosuppression and mitigate side effects. To illustrate, Johnson & Johnson, an American pharmaceutical and biotechnology firm, secured approval from the U.S. Food and Drug Administration (FDA) in March 2024 for OPSYNVI. OPSYNVI is a single-pill mix of tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and macitentan, an endothelin receptor antagonist (ERA), and is intended for long-term management of pulmonary arterial hypertension (PAH). OPSYNVI can be administered to PAH patients who are either new to treatment or are already on an ERA, PDE5 inhibitor, or both. Patients who are regularly taking macitentan 10 mg and tadalafil 40 mg (20 mg x 2) in separate tablets can be given OPSYNVI.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10143
Which regions are most influential in expanding the organ transplant immunosuppressant drugs market?
North America was the largest region in the organ transplant immunosuppressant drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Application Development Software Global Market Report 2024
Application Security Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/application-security-global-market-report
Managed Security Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/managed-security-services-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
